Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2020. Start Trial.
Date Value
September 30, 2026 76.22M
June 30, 2026 76.69M
March 31, 2026 79.26M
December 31, 2025 82.04M
September 30, 2025 80.54M
June 30, 2025 85.43M
March 31, 2025 87.53M
December 31, 2024 91.43M
September 30, 2024 95.04M
June 30, 2024 96.44M
March 31, 2024 101.81M
December 31, 2023 106.24M
Date Value
September 30, 2023 110.24M
June 30, 2023 110.94M
March 31, 2023 107.73M
December 31, 2022 102.30M
September 30, 2022 96.59M
June 30, 2022 90.14M
March 31, 2022 82.84M
December 31, 2021 77.10M
September 30, 2021 71.35M
June 30, 2021 67.83M
March 31, 2021 63.35M
December 31, 2020 56.64M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

View Research and Development Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (TTM) Benchmarks

View Research and Development Expense (TTM) Benchmarks
Start Trial
Anavex Life Sciences Corp. 11.44M
Vaxcyte, Inc. 1.093B
Connect Biopharma Holdings Ltd. 55.37M
Caribou Biosciences, Inc. 84.72M
Oncolytics Biotech, Inc. 13.18M